Finanzen von Polaryx Therapeutics, Inc (PLYX)PLYXPolaryx Therapeutics, Inc

In the context of the broader market, PLYX competes directly with industry leaders such as RGP and WFCF. With a market capitalization of $86.74M, it holds a significant position in the sector. When comparing efficiency, PLYX's gross margin of N/A stands against RGP's 36.47% and WFCF's 40.58%. Such benchmarking helps identify whether Polaryx Therapeutics, Inc is trading at a premium or discount relative to its financial performance.

Polaryx has shown a consistent negative net income, with losses increasing to $2,544,000 in Q1 2026. The current ratio is strong at 13.53, indicating good short-term financial health despite ongoing losses.